Log In
BCIQ
Print this Print this
 

Zuplenz, ondansetron

  Manage Alerts
Collapse Summary General Information
Company MonoSol Rx LLC
DescriptionSelective serotonin (5-HT3) receptor antagonist
Molecular Target Serotonin (5-HT3) receptor
Mechanism of ActionSerotonin (5-HT3) receptor antagonist
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationEmesis
Indication DetailsPrevent and treat nausea and vomiting; Prevent postoperative chemotherapy-induced and radiotherapy-induced nausea and vomiting
Regulatory Designation
PartnerGalena Biopharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

2

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

07/22/2014

Undisclosed

Undisclosed

Undisclosed

01/21/2013

Undisclosed

Undisclosed

0

Get a free BioCentury trial today